We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+12.16%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$718B
AUM Growth
+$49.7B
Cap. Flow
-$15.6B
Cap. Flow %
-2.17%
Top 10 Hldgs %
31.75%
Holding
3,044
New
123
Increased
1,636
Reduced
968
Closed
150

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.11B
2
META icon
Meta Platforms (Facebook)
META
+$2.59B
3
EQT icon
EQT Corp
EQT
+$1.31B
4
CL icon
Colgate-Palmolive
CL
+$1.08B
5
ADBE icon
Adobe
ADBE
+$1.06B

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$1.92B
2
UNH icon
UnitedHealth
UNH
+$1.78B
3
AMD icon
Advanced Micro Devices
AMD
+$1.55B
4
ROST icon
Ross Stores
ROST
+$1.54B
5
ASML icon
ASML
ASML
+$1.49B

Sector Composition

Rank Sector Weight
1 Technology 31.61%
2 Healthcare 16.91%
3 Consumer Discretionary 11.05%
4 Financials 10.6%
5 Communication Services 9.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TLS icon
2751
Telos
TLS
$327M
$70K ﹤0.01%
27,006
-9,613
-26% -$22.8K
CONN
2752
DELISTED
Conn's Inc.
CONN
$70K ﹤0.01%
18,700
-16,743
-47% -$75.8K
ADAP
2753
DELISTED
Adaptimmune Therapeutics
ADAP
$69K ﹤0.01%
+73,922
New +$88.1K
AP icon
2754
Ampco-Pittsburgh
AP
$191M
$69K ﹤0.01%
21,600
APVO icon
2755
Aptevo Therapeutics
APVO
$5.34M
0
IQ icon
2756
iQIYI
IQ
$1.27B
$68K ﹤0.01%
12,700
KZR
2757
DELISTED
Kezar Life Sciences
KZR
$68K ﹤0.01%
2,765
+201
+8% +$5.23K
ZOM
2758
DELISTED
Zomedica Corp.
ZOM
$67K ﹤0.01%
332,000
CLSK icon
2759
CleanSpark
CLSK
$3.03B
$66K ﹤0.01%
15,255
+1,495
+11% +$6K
HRTX icon
2760
Heron Therapeutics
HRTX
$63.6M
$66K ﹤0.01%
56,604
+2,047
+4% +$3.65K
VRM icon
2761
Vroom Inc
VRM
$52.3M
$66K ﹤0.01%
570
AHT
2762
Ashford Hospitality Trust
AHT
$20.1M
$65K ﹤0.01%
1,730
+213
+14% +$8.01K
CVM icon
2763
CEL-SCI Corp
CVM
$25.5M
$65K ﹤0.01%
893
SST icon
2764
System1
SST
$18.9M
$65K ﹤0.01%
+1,435
New +$54.3K
TCRT icon
2765
Alaunos Therapeutics
TCRT
$4.86M
$63K ﹤0.01%
813
-93
-10% -$7.52K
WVVI icon
2766
Willamette Valley Vineyards
WVVI
$11.7M
$63K ﹤0.01%
10,850
RFL icon
2767
Rafael Holdings
RFL
$108M
$62K ﹤0.01%
29,731
NAGE
2768
Niagen Bioscience
NAGE
$241M
$62K ﹤0.01%
39,300
ASRT
2769
DELISTED
Assertio
ASRT
$61K ﹤0.01%
+747
New +$69.4K
CUE icon
2770
Cue Biopharma
CUE
$121M
$61K ﹤0.01%
+555
New +$65.2K
STTK icon
2771
Shattuck Labs
STTK
$745M
$61K ﹤0.01%
19,300
BTBT icon
2772
Bit Digital
BTBT
$530M
$60K ﹤0.01%
+14,678
New +$38K
SMMT icon
2773
Summit Therapeutics
SMMT
$11.8B
$60K ﹤0.01%
+23,512
New +$42.9K
BMTX
2774
DELISTED
BM Technologies, Inc.
BMTX
$60K ﹤0.01%
19,800
ABUS icon
2775
Arbutus Biopharma
ABUS
$908M
$59K ﹤0.01%
25,629
+4,134
+19% +$10.8K

Similar funds

T. Rowe Price Associates's Q2 2023 Portfolio in Review

As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
  • T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
  • T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
  • T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
  • T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
  • T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
  • T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.